RecruitingPhase 3NCT07267806

Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Linhui Peng
Intervention
Infusional mFOLFOX7 plus Camrelizumab and apatinib(drug)
Enrollment
326 target
Eligibility
18 years · All sexes
Timeline
20252032

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07267806 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials